[1S-(1α,6β,7α,8β,8aβ)]-octahydro-1,6,7,8-indolizinetetrol 6-octanoate | 128741-86-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚里西啶
• 英文名称: [1S-(1α,6β,7α,8β,8aβ)]-octahydro-1,6,7,8-indolizinetetrol 6-octanoate
• 英文别名: [(1S,6S,7S,8R,8aR)-1,7,8-trihydroxy-1,2,3,5,6,7,8,8a-octahydroindolizin-6-yl] octanoate
• CAS: 128741-86-6
• 化学式: C₁₆H₂₉NO₅
• 分子量: 315.41
• InChiKey: NKURCTMTURLHRY-BHQQPIICSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  22
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  90.2
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  栗精胺 、 辛酰氯 在 二正丁基氧化锡 、 三乙胺 作用下， 生成 [1S-(1α,6β,7α,8β,8aβ)]-octahydro-1,6,7,8-indolizinetetrol 6-octanoate
  参考文献：
  名称：

  粟精胺的简便选择性酰化

  摘要：

  通过原位使用预先形成的二丁基有机锡衍生物，已实现了对多羟基化吲哚并立生物碱粟精胺（1）的6-羟基基团的轻松选择性酰化。

  DOI：

  10.1016/s0040-4039(00)94361-2

文献信息

• Anti-herpes castanospermine esters
  申请人：MERRELL DOW PHARMACEUTICALS INC.

  公开号：EP0492841A1

  公开（公告）日：1992-07-01

  Castanospermine esters are active in the treatment of herpes viral infections.

  蓖麻油酯在治疗疱疹病毒感染方面具有活性。
• ANDERSON, WAYNE K.;COBURN, ROBERT A.;GOPALSAMY, ARIAMALA;HOWE, TREVOR J., TETRAHEDRON LETT., 31,(1990) N, C. 169-170
  作者：ANDERSON, WAYNE K.、COBURN, ROBERT A.、GOPALSAMY, ARIAMALA、HOWE, TREVOR J.

  DOI：——

  日期：——
• USE OF CASTANOSPERMINE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C
  申请人：Virogen Ltd.

  公开号：EP1387681B1

  公开（公告）日：2008-08-20
• Compositions and methods for treating or preventing Hepadnaviridae infection
  申请人：Dugourd Dominique

  公开号：US20060052414A1

  公开（公告）日：2006-03-09

  The present disclosure relates generally to the use of certain castanospermine esters to treat or prevent infections caused by Hepadnaviridae, particularly infections caused by hepatitis B virus (HBV), and to the use of such compounds to examine the biological mechanisms of HBV infection.
• Compositions and methods for treating or preventing flaviviridae infections
  申请人：Dugourd Dominique

  公开号：US20060194835A1

  公开（公告）日：2006-08-31

  The present disclosure relates generally to compositions having a glucosidase inhibitor (castanospermine or a derivative thereof, such as celgosivir) in combination with adjunctive therapies of compounds that alter immune function (such as interferon) and compounds that alter viral replication (such as nucleoside analogues like ribavirin), which can be used to treat or prevent infections caused by or associated with a virus of the Flaviviridae family, particularly infections caused by or associated with Hepatitis C virus (HCV).